There are two classes of bronchodilators for airway diseases as asthma and COPD. We can do salbutamol bronchodilator test with a particular class to assess the treatment responsiveness but cannot do so for the other class (AMA, antimuscarinic agents) in a clinic setting. We have evolved a protocol with a short-onset but long acting AMA glycopyrronium that dictates the AMA sensitivity in a patient of airway disease. This will help immensely to phenotype airway diseases and decide customized treatment.

{European Respiratory Journal 54(suppl 63) PA2480;DOI:10.1183/13993003}, {submitted to JACP (manuscript ID:JACP_34_20)}